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reportedly different from women included in the analysis. The
investigators indicated that they were younger and thus more likely
to harbor HPV deoxyribonucleic acid but probably less likely to
present CVD than the “responders.”
Third, of the 44 women with cervical cancer listed in the their
Table 1 (1), 22 were HPV negative. This is not consistent with the
fact that HPV is the etiologic agent for cervical cancer.
Fourth, in their Table 3, Kuo and Fujise (1) presented the odds
ratios (ORs) for CVD comparing women with cancer-associated
HPV types or other HPV types with those who are negative for
HPV. In the first model, the OR was 2.87 for women with
cancer-associated HPV types. The OR was 2.13 for women with
other HPV types, namely, low-risk HPV types that are not able to
induce p53 and pRB degradation. If the physiopathology hypoth-
esis is correct, we would expect a nonsignificant OR. As for models
2, 3, and 4, we would also expect lower ORs for CVD in women
with other HPV types.
Finally, the overall physiopathology hypothesis is very unlikely.
Indeed, HPV fails to produce classic viremia. Rather the virus
replicates locally until it is cleared by an efficient immune response.
In case of viral persistence, the virus remains localized to the site of
infection, and associated lesions can occur after an increased
expression of E6 and E7. The virus does not disseminate through-
out the body. It is therefore very unlikely that E6 and E7 have a
systemic effect leading to atherosclerosis.
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Reply
We thank Dr. Prétet and colleagues for their insightful comments
on our report (1). Brief, point-by-point responses provided here
illuminate the need for further research on the link between human
papillomavirus (HPV) infection and atherosclerosis.
First, on the basis of recent survey from the National Health
and Nutrition Examination Survey 2003 to 2006, the weighted
prevalence of genital HPV infection among 2,787 women wasestimated to be 44.5% (2), which is close to the unweighted
prevalence we reported (46.6%) (1). Using the research use–only
Linear Array genotyping assay (Roche Diagnostics GmbH,
Mannheim, Germany) has resulted in a higher HPV prevalence
than previously reported (3).
Second, we do not know if the “nonresponders” (n  543) were
more likely to harbor HPV deoxyribonucleic acid, because they did
not submit swab specimens or submitted inadequate swab speci-
mens. The crude prevalence of cardiovascular disease (CVD)
among responders and nonresponders was 2.6% and 2.2%, respec-
tively (p  0.612).
Third, ascertainment of cervical cancer was by self-report and
may have suffered from recall bias and a certain degree of
disagreement as to “true measures” of cervical cancer compared to
“self-report.” We reanalyzed the data for the HPV-CVD associ-
ation without using self-reported cervical cancer as a covariate, and
the results were the same.
Fourth, the association between other HPV types and CVD was
significant in model 1 (odds ratio: 2.13; 95% confidence interval:
1.12 to 4.06) but not in models 2 to 5. Low socioeconomic status,
associated with both HPV infection and CVD, is an important
confounder for which we were not able to control (4).
Finally, although the mechanism by which HPV infection could
promote atherosclerosis remains unknown, several possibilities
exist. First, chronic local inflammation caused by HPV infection
and resultant circulatory inflammatory mediators can facilitate
atherosclerosis as seen in Porphyromonas gingivalis infection (5).
Second, macrophages and monocytes (M) recruited to HPV-
infected tissue (6,7) can take up the virus (8), leading to the
degradation of M-p53 by E6 and E7. HPV-infected M can
then enter atherosclerotic plaques and facilitate atherosclerosis.
The lack of functional p53 in M facilitates atherosclerosis in
mouse models of atherosclerosis (9,10). These hypotheses, al-
though plausible, need to be experimentally tested.
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Echocardiographic Evaluation
of Pulmonary Artery Pressure
in Patients With Heart Failure
We read with great interest the report by Bursi et al. (1) on the
prognostic value of pulmonary pressure in heart failure (HF).
The investigators used Doppler-determined pulmonary artery
systolic pressure (PASP), which requires an estimation of right
atrial pressure by the diameter and respiratory variation of the
inferior vena cava. This approach was initially followed to
provide values comparable with those of right-heart catheter-
ization. However, the almost arbitrary estimation of right atrial
pressure and the use of reference values for PASP derived by
right-heart catheterization worsen the reproducibility and reli-
ability of Doppler measurements. We first identified this
problem 15 years ago while studying pulmonary hypertension in
beta-thalassemia, and we proposed the use of tricuspid regur-
gitant velocity and peak systolic tricuspid pressure gradient
alone (2). To determine a reference range for tricuspid pressure
radient, we studied a group of healthy subjects and found an
pper normal limit of 30 mm Hg, which corresponds to a
ricuspid regurgitant velocity of 2.7 m/s (3). At present,
ricuspid regurgitant velocity, with a threshold of 2.7 m/s, is the
roposed method for the echocardiographic screening of pul-
onary hypertension (3).
A tricky aspect in the echocardiographic evaluation of PASP
in HF is the loading conditions at the time of examination (4).
Patients with acute HF and lung congestion would have
considerably high PASP reflecting the acutely increased left
ventricular filling pressures, not the true, steady-state passive
and active component of pulmonary hypertension. This param-
eter should be taken under consideration while evaluating
patients with acute HF, and the examination should be repeated
after clinical stabilization. Furthermore, it should be stressed
that ejection fraction is a rough estimate of systolic left
ventricular function, and this may account for the lack of
association between PASP and systolic dysfunction severity
observed by Bursi et al. (1).
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Reply
We thank Drs. Farmakis and Aessopos for the opportunity to
clarify important aspects of the prognostic use of pulmonary artery
systolic pressure (PASP) measured by Doppler in patients with
heart failure (1). Although Doppler is the preferred tool to measure
pulmonary pressures in practice (2), we agree that the estimation of
right atrial pressure has limitations (3).
The upper limit of normal of 2.7 m/s corresponding to a peak
gradient of 30 mm Hg was tested in a small group of younger
(mean age 38.9  12.7 years), healthy, nonsmoking subjects (4).
Thus, it is applicable to similar, relatively young populations
such as patients with beta-thalassemia or pulmonary arterial
hypertension and when right atrial pressure is thought to be
normal (5). Hence, this cutoff is of less relevance in older
populations with greater comorbidity, as PASP increases with
age, and patients with heart failure are elderly. Because there is
no universally accepted cutoff value to define pulmonary hyper-
tension, we analyzed the entire distribution of pulmonary
pressures and analyzed PASP with tertiles or continuously,
rather than applying an arbitrary cutoff. We showed that the
higher the PASP, the worse the prognosis, and the estima-
tion of right atrial pressure has no bearing on this continuum of
risk.
We defined heart failure by epidemiological criteria, and our
goal was not to distinguish the acute increase in filling pressures
from the chronic passive or active component of pulmonary
hypertension. We demonstrated that Doppler estimation of PASP
was feasible in most patients (91%) in the community and that
when elevated, it strongly and independently predicted outcome
regardless of the mechanism of pulmonary hypertension.
